Drug Profile
IVN 201
Alternative Names: Cat-MAT; IVN201Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ImVisioN GmbH
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Allergy in Switzerland (Intralymphatic, Injection)
- 19 Mar 2009 ImVisioN completes a phase I trial in Allergy in Switzerland
- 10 Sep 2008 Phase-I clinical trials in Allergy in Switzerland (Intralymphatic)